Search
Search Results
-
Lecanemab: Appropriate Use Recommendations
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer’s disease (AD) to be initiated in early AD (mild cognitive...
-
Lecanemab: More Questions Than Answers!
The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer’s disease....
-
Lecanemab: First Approval
Lecanemab (lecanemab-irmb; LEQEMBI™) is a humanized immunoglobulin gamma 1 (IgG1) against aggregated soluble and insoluble forms of amyloid-β...
-
Advancing Alzheimer’s care: a novel therapy with lecanemab
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects the patient’s quality of life. The current regime of drugs only...
-
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer’s Disease
BackgroundLecanemab is a humanized IgG1 monoclonal antibody binding with high affinity to amyloid-beta protein protofibrils. In phase 3 development,...
-
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Alzheimer’s disease (AD) is a neurodegenerative condition that causes cognitive decline, memory loss, and reduced personal autonomy. The pathology of...
-
Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
IntroductionAlzheimer’s disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible...
-
Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
IntroductionAlzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with memory, cognitive, and behavioral deficits, and...
-
The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Alzheimer’s disease, prevalent in individuals aged 60 and above, constitutes most dementia cases and significantly impairs memory and cognitive...
-
A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial
IntroductionAlzheimer’s disease (AD), a progressive neurodegenerative disease, is the main cause of dementia and one of the leading causes of death...
-
The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
IntroductionAlzheimer’s disease (AD) is a progressive, neurodegenerative disease that affects memory, thinking, and behavior and places a substantial...
-
Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
IntroductionAlzheimer’s disease (AD) is a progressive, neurodegenerative disease and is the most common cause of dementia. Lecanemab is a humanized...
-
